Roivant Sciences Net Income decreased by 134.2% to -$265.89M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 257.0%, from $169.38M to -$265.89M. Over 3 years (FY 2021 to FY 2024), Net Income shows an upward trend with a -41.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher values indicate greater profitability and financial health, directly impacting shareholder value.
The final bottom-line profit of the company after all operating expenses, non-operating expenses, and income taxes have...
The most common metric for evaluating company performance against industry competitors.
net_income| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$82.18M | -$208.48M | -$284.54M | -$270.06M | -$331.81M | -$291.59M | -$352.01M | -$33.62M | -$291.82M | -$304.33M | $5.10B | $0.00 | $95.30M | -$230.18M | $169.38M | -$206.48M | -$223.36M | -$113.52M | -$265.89M |
| QoQ Change | — | -153.7% | -36.5% | +5.1% | -22.9% | +12.1% | -20.7% | +90.5% | -768.1% | -4.3% | >999% | -100.0% | — | -341.5% | +173.6% | -221.9% | -8.2% | +49.2% | -134.2% |
| YoY Change | — | — | — | — | -303.7% | -39.9% | -23.7% | +87.6% | +12.1% | -4.4% | >999% | +100.0% | +132.7% | +24.4% | -96.7% | — | -334.4% | +50.7% | -257.0% |
| Segment | Q3 '25 | Q4 '25 |
|---|---|---|
| Reportable Segment | -$166.04M | -$313.70M |
| Total | -$113.52M | -$265.89M |